27 Mar
  • By CureDuchenne User
  • Cause in

Catabasis Connection – March 2019

In the latest Catabasis Connection, they take us behind-the-scenes with the PolarisDMD experience. Learn what it’s like to participate in their PolarisDMD clinical trial. Read the full newsletter here.

READ MORE
14 Feb
  • By Jessica Yanez-Perez
  • Cause in

The Phase 3 PolarisDMD Trial Goes Global

With a flurry of recent activity, 17 trial sites are now open for enrollment. We are especially excited to share that our first international sites in Canada and Australia have launched. Sites are also expected to launch soon in Europe and Israel.

READ MORE
06 Feb
  • By CureDuchenne User
  • Cause in

NS Pharma Community Letter

We are excited that our industry partner, NS Pharma, has applied for accelertated approval for it’s exon 53 skipping therapy, viltolarsen. We applaud the dedication to the Duchenne community by NS Pharma and look forward to continued success. NS Pharma Community Letter

READ MORE
12 Oct
  • By CureDuchenne User
  • Cause in

Sarepta Therapeutics Advocacy Newsletter October 2018

Dear Duchenne Advocacy Leaders, Lately we have heard many stop to consider the progress made in the last decade in Duchenne treatment and care. Improvements have been driven by this community – by you – and organization around key topics like care considerations and standards of care, a topic well chosen for this year’s World […]

READ MORE